Inside the Engine Room of Modern Drug Discovery: A Masterclass with Dr. Lloyd Klickstein

The complex journey from a theoretical biological target to an FDA-approved medicine is one of the most resource-intensive, high-risk, and scientifically demanding processes in modern civilization. In a recent deep-dive discussion on The Peter Attia Drive, physician-scientist Dr. Lloyd Klickstein demystified this "black box" of biotechnology, detailing the rigorous intersection of academic research, regulatory navigation, and capital allocation. With a career spanning over two decades at the forefront of translational medicine—including pivotal roles at Novartis and as a co-founder of Versanis Bio—Dr. Klickstein provides a rare, granular look at the economic and scientific machinery that dictates the future of human health.

The Evolution of Translational Medicine

The traditional model of drug development often suffered from a disconnect between bench-side laboratory research and bedside clinical application. Dr. Klickstein’s career trajectory mirrors the industry’s shift toward "translational medicine," a discipline that seeks to bridge this gap by prioritizing the rapid application of scientific discoveries to patient populations. After completing his MD and PhD at Harvard Medical School and training at Brigham and Women’s Hospital, Klickstein spent nearly twenty years at Novartis. There, he helped pioneer the "New Indication Discovery Unit," an organizational structure designed to identify secondary uses for existing molecular entities and to accelerate the validation of novel therapeutic targets.

This approach marked a departure from the "shotgun" methods of the past. Instead, it favored a hypothesis-driven strategy where unmet medical needs—ranging from rare autoimmune conditions to the degenerative processes of aging—were assessed through the lens of feasibility, biological plausibility, and regulatory pathway clarity.

The Lifecycle of a Molecule: From Concept to Clinic

Dr. Klickstein delineates the drug discovery arc into several distinct, high-stakes phases. The process begins with the identification of a biological target, such as a protein or signaling pathway, that plays a causative role in a disease. Once a target is identified, the challenge shifts to engineering a molecule—either a small-molecule drug, which can typically enter cells and be administered orally, or a biologic, such as a monoclonal antibody, which is larger, more complex, and generally delivered via injection.

The engineering phase is followed by extensive preclinical testing, where researchers must prove both the safety and the "proof of concept" in animal models. This stage is notoriously perilous; the vast majority of candidates fail here due to toxicity or lack of efficacy. Only after satisfying stringent preclinical requirements can a company submit an Investigational New Drug (IND) application to the FDA. The subsequent clinical trials are divided into phases: Phase I evaluates safety in small groups; Phase II assesses efficacy and side effects; and Phase III, often the most expensive and time-consuming stage, confirms efficacy across a larger, more diverse patient population.

Case Study: The Pivot of Bimagrumab

A primary focus of the discussion is the development of bimagrumab, a human monoclonal antibody designed to bind to activin type II receptors. Initially developed to address muscle wasting, the drug’s trajectory serves as a prime example of why early clinical failure or unexpected findings can lead to profound breakthroughs. During early trials, researchers observed that patients receiving bimagrumab experienced significant reductions in fat mass alongside improvements in metabolic health markers associated with type 2 diabetes.

This discovery prompted a strategic pivot. By repurposing bimagrumab from a muscle-wasting treatment to a potential obesity therapy, the development team effectively unlocked new clinical utility. This evolution reached a high point when Versanis Bio, the company Klickstein co-founded, was acquired by Eli Lilly for a deal valued at up to $1.925 billion. The success of bimagrumab illustrates the "serendipity of science"—where diligent monitoring of patient outcomes in early-stage trials reveals indications that were not part of the original design.

Economic Realities and Capital Allocation

Drug development is as much an economic endeavor as it is a scientific one. Dr. Klickstein emphasizes that the exorbitant costs associated with bringing a drug to market—often exceeding $2 billion when accounting for failed projects—are driven by the sheer scale of manufacturing requirements and the complexity of clinical operations.

The requirement for Good Manufacturing Practice (GMP) is a significant barrier to entry. Companies must prove they can produce a drug with consistent purity, potency, and safety at scale. This involves building specialized facilities and navigating complex supply chains, often years before a drug receives commercial approval. Furthermore, the allocation of capital remains a zero-sum game: investors must decide whether to pour resources into a "moonshot" project with high potential reward but high risk, or into incremental improvements that offer more predictable, albeit smaller, returns. Dr. Klickstein argues that the industry’s greatest challenge is not merely scientific, but the ability to "fail fast." Identifying that a drug will not work as early as possible is a critical competency that preserves capital for more promising candidates.

Frontiers in Geroprotection and Cancer Prevention

Beyond the mechanics of current drug development, the conversation highlights the shifting paradigm of medicine toward preventive interventions. Dr. Klickstein has been instrumental in exploring mTOR (mechanistic target of rapamycin) inhibition, a pathway deeply implicated in the regulation of cellular growth and aging. The landmark trials he co-led with Joan Mannick on immunosenescence—the decline of the immune system with age—demonstrated that it is possible to pharmacologically intervene in the biological processes of aging to improve immune function.

Looking ahead, Dr. Klickstein is shifting his focus to a novel pharmacologic approach to cancer prevention. The ambition here is to move medicine from a reactive state—treating cancer once it has manifested—to a proactive state, where molecular interventions prevent the formation or progression of malignant cells entirely. This field, known as geroprotection, seeks to extend the "healthspan" of the population, not just the lifespan.

Broader Implications for Healthcare

The insights shared by Dr. Klickstein highlight an essential truth for patients and policymakers alike: the development of new medicine is a long-game marathon. The regulatory and economic hurdles are not arbitrary; they are the safeguards against the introduction of unsafe or ineffective treatments. However, the complexity of the process can sometimes stifle innovation.

The shift toward precision medicine and the application of biologics suggests that the next decade will be defined by a more nuanced understanding of individual biology. As Dr. Klickstein suggests, the ability to treat conditions like obesity and metabolic dysfunction with high-precision antibodies or gene therapies marks a "quantum step" in medicine. However, the successful integration of these tools into the healthcare system will depend on continued transparency regarding the cost of development and a sustained commitment to rigorous, evidence-based research.

Ultimately, the behind-the-scenes look at the life of a physician-scientist reveals that while the laboratory is where the science begins, the true impact of any medicine is only realized when it safely crosses the threshold into the lives of patients. For the scientific community, the imperative remains clear: to develop treatments that are not only scientifically sound but also economically sustainable, ensuring that the next generation of life-saving interventions is accessible to those who need them most.